Management of relapse after allo-SCT for AML and the role of second transplantation

被引：59
作者：
Savani, B. N. [1 ]
Mielke, S. [2 ]
Reddy, N. [1 ]
Goodman, S. [1 ]
Jagasia, M. [1 ]
Rezvani, K. [3 ]
机构：
[1] Vanderbilt Univ, Dept Med, Hematol & Stem Cell Transplantat Sect, Div Hematol Oncol,Med Ctr, Nashville, TN 37232 USA
[2] Univ Wurzburg, Dept Internal Med 2, Div Hematol & Oncol, Allogene Stem Cell Transplant Ctr, Wurzburg, Germany
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp Trust, Dept Haematol, London, England
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 44卷 / 12期
关键词：
AML; relapse; transplantation; DLI; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; DONOR LEUKOCYTE INFUSIONS; VERSUS-HOST-DISEASE; HEMATOPOIETIC PROGENITOR CELLS; ALLOGENEIC TRANSPLANTATION; HEMATOLOGIC MALIGNANCIES; EXTRAMEDULLARY RELAPSE; GEMTUZUMAB OZOGAMICIN;
D O I：
10.1038/bmt.2009.300
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT. Bone Marrow Transplantation (2009) 44, 769-777; doi: 10.1038/bmt.2009.300; published online 26 October 2009
引用
收藏
页码：769 / 777
页数：9
相关论文
共 68 条
[1]  
Al-Qurashi F, 2004, Hematology, V9, P123
[2]   Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation [J].
Alessandrino, EP ;
Bernasconi, P ;
Caldera, D ;
Colombo, A ;
Malcovati, L ;
Martinelli, G ;
Bonfichi, M ;
Pagnucco, G ;
Salvaneschi, L ;
Bernasconi, C .
BONE MARROW TRANSPLANTATION, 1999, 23 (06) :607-612
[3]   Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience [J].
Arellano, Martha L. ;
Langston, Amelia ;
Winton, Elliott ;
Flowers, Christopher R. ;
Waller, Edinind K. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) :116-123
[4]   Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents [J].
Barrett, A. J. ;
Savani, B. N. .
LEUKEMIA, 2006, 20 (10) :1661-1672
[5]   Allogeneic stem cell transplantation for myelodysplastic syndrome [J].
Barrett, A. John ;
Savani, Bipin N. .
SEMINARS IN HEMATOLOGY, 2008, 45 (01) :49-59
[6]   2ND TRANSPLANTS FOR LEUKEMIC RELAPSE AFTER BONE-MARROW TRANSPLANTATION - HIGH EARLY MORTALITY BUT FAVORABLE EFFECT OF CHRONIC GVHD ON CONTINUED REMISSION - A REPORT BY THE EBMT-LEUKEMIA-WORKING-PARTY [J].
BARRETT, AJ ;
LOCATELLI, F ;
TRELEAVEN, JG ;
GRATWOHL, A ;
SZYDLO, R ;
ZWAAN, FE .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (04) :567-574
[7]   Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia [J].
Berthou, C ;
Léglise, MC ;
Herry, A ;
Balcon, D ;
Hardy, E ;
Lessard, M ;
Abgrall, JF .
LEUKEMIA, 1998, 12 (11) :1676-1681
[8]   Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: Effect of interventions on outcome [J].
Bethge, WA ;
Storer, BE ;
Maris, MB ;
Flowers, MED ;
Maloney, DG ;
Chauncey, TR ;
Woolfrey, AE ;
Storb, R ;
Sandmaier, BM .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (10) :974-980
[9]   Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation [J].
Bosi, A ;
Laszlo, D ;
Labopin, M ;
Reffeirs, J ;
Michallet, M ;
Gluckman, E ;
Alessandrino, PE ;
Locatelli, F ;
Vernant, JP ;
Sierra, J ;
Jouet, JP ;
Frassoni, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3675-3684
[10]   The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse [J].
Carlens, S ;
Remberger, M ;
Aschan, J ;
Ringdén, O .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (01) :31-38
1234567